Trials / Completed
CompletedNCT04916509
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region Like Saudi Arabia, UAE and Other GCC Countries: A Retrospective Study (Treasure Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 258 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
retrospective non-interventional study (NIS) that aims to describe the demographics, clinical characteristics, clinical outcomes, and treatment patterns, among patients receiving palbociclib for the treatment of HR+/HER2- metastatic/locally advanced breast cancer (BC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Palbociclib plus an aromatase inhibitor | Palbociclib plus an aromatase inhibitor therapy |
| DRUG | Palbociclib plus fulvestrant | Palbociclib plus fulvestrant |
Timeline
- Start date
- 2021-09-13
- Primary completion
- 2022-12-27
- Completion
- 2022-12-27
- First posted
- 2021-06-07
- Last updated
- 2023-06-06
Locations
7 sites across 3 countries: Qatar, Saudi Arabia, United Arab Emirates
Source: ClinicalTrials.gov record NCT04916509. Inclusion in this directory is not an endorsement.